BC Innovations | Oct 29, 2019
Distillery Therapeutics

Combined inhibition of G12C-mutant KRAS, mTOR and IGF1R for NSCLC

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) Triple therapy with KRAS-G12C, mTOR and IGF1R inhibitors could treat KRAS G12C-mutant NSCLC. Whole genome screening of an shRNA library for targets whose inhibition enhanced the...
BioCentury | Oct 4, 2019
Finance

Selectivity sets off $37M series A for mTOR company Aeovian

Preclinical selectivity data for Aeovian’s mTORC1 inhibitor prompted venBio and Sofinnova Investments to co-lead the biotech’s $37 million series A after long eyeing the space. “mTORC1 selective inhibition has been a Holy Grail target in...
BC Extra | Jun 18, 2019
Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
BioCentury | May 10, 2019
Product Development

Exelixis to fuel pipeline growth with Cabometyx cash flows

On the back of the successful launch of Cabometyx cabozantinib, Exelixis is not only using the increased free cash flow to expand the drug’s label, it also thinks it has the firepower to build out...
BC Extra | Sep 14, 2018
Company News

ACS’s Brawley disappointed in Baselga resignation

American Cancer Society Chief Medical and Scientific Officer Otis Brawley said he was disappointed that José Baselga resigned from Memorial Sloan Kettering Cancer Center after failing to disclose financial ties to industry. Baselga, who was...
BC Week In Review | Jul 27, 2018
Clinical News

resTORbio forging ahead with anti-infective after Phase IIb readout

Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent respiratory tract infections showed that all three dose regimens of the candidate missed the study's primary endpoint vs....
BC Extra | Jul 25, 2018
Clinical News

resTORbio forging ahead with anti-infective after Phase IIb readout

Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent respiratory tract infections showed that all three dose regimens of the candidate missed the study's primary endpoint vs....
BC Week In Review | May 18, 2018
Company News

FDA names, shames ‘anticompetitive’ drug companies

FDA Commissioner Scott Gottlieb Thursday made public a list of 41 branded drug companies that generics manufacturers have accused of blocking access to drug samples to thwart development of competitive generic drugs. The list includes...
BC Extra | May 17, 2018
Politics & Policy

FDA names, shames ‘anticompetitive’ drug companies

FDA Commissioner Scott Gottlieb Thursday made public a list of 41 branded drug companies that generics manufacturers have accused of blocking access to drug samples to thwart development of competitive generic drugs. The list includes...
BioCentury | Feb 17, 2018
Product Development

This year’s model

Companies are answering FDA’s push for model-informed dose optimization in cancer by modeling how tumors grow and how tumor kinetics relate to outcomes. The models can support dosing decisions and help companies make faster, better...
Items per page:
1 - 10 of 439